» Articles » PMID: 38902597

Potential Mechanisms of Cancer Prevention and Treatment by Sulforaphane, a Natural Small Molecule Compound of Plant-derived

Overview
Journal Mol Med
Publisher Biomed Central
Date 2024 Jun 20
PMID 38902597
Authors
Affiliations
Soon will be listed here.
Abstract

Despite recent advances in tumor diagnosis and treatment technologies, the number of cancer cases and deaths worldwide continues to increase yearly, creating an urgent need to find new methods to prevent or treat cancer. Sulforaphane (SFN), as a member of the isothiocyanates (ITCs) family, which is the hydrolysis product of glucosinolates (GLs), has been shown to have significant preventive and therapeutic cancer effects in different human cancers. Early studies have shown that SFN scavenges oxygen radicals by increasing cellular defenses against oxidative damage, mainly through the induction of phase II detoxification enzymes by nuclear factor erythroid 2-related factor 2 (Nrf2). More and more studies have shown that the anticancer mechanism of SFN also includes induction of apoptotic pathway in tumor cells, inhibition of cell cycle progression, and suppression of tumor stem cells. Therefore, the application of SFN is expected to be a necessary new approach to treating cancer. In this paper, we review the multiple molecular mechanisms of SFN in cancer prevention and treatment in recent years, which can provide a new vision for cancer treatment.

Citing Articles

Impact of Sulforaphane on Breast Cancer Progression and Radiation Therapy Outcomes: A Systematic Review.

Alhazmi N, Subahi A Cureus. 2025; 17(1):e78060.

PMID: 40013196 PMC: 11863992. DOI: 10.7759/cureus.78060.

References
1.
Han S, Wang Z, Liu J, Wang H, Yuan Q . miR-29a-3p-dependent COL3A1 and COL5A1 expression reduction assists sulforaphane to inhibit gastric cancer progression. Biochem Pharmacol. 2021; 188:114539. DOI: 10.1016/j.bcp.2021.114539. View

2.
Xu Y, Han X, Li Y, Min H, Zhao X, Zhang Y . Sulforaphane Mediates Glutathione Depletion via Polymeric Nanoparticles to Restore Cisplatin Chemosensitivity. ACS Nano. 2019; 13(11):13445-13455. DOI: 10.1021/acsnano.9b07032. View

3.
Zhang Y, Gilmour A, Ahn Y, de la Vega L, Dinkova-Kostova A . The isothiocyanate sulforaphane inhibits mTOR in an NRF2-independent manner. Phytomedicine. 2019; 86:153062. PMC: 8106549. DOI: 10.1016/j.phymed.2019.153062. View

4.
Negrette-Guzman M . Combinations of the antioxidants sulforaphane or curcumin and the conventional antineoplastics cisplatin or doxorubicin as prospects for anticancer chemotherapy. Eur J Pharmacol. 2019; 859:172513. DOI: 10.1016/j.ejphar.2019.172513. View

5.
Royston K, Paul B, Nozell S, Rajbhandari R, Tollefsbol T . Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms. Exp Cell Res. 2018; 368(1):67-74. PMC: 6733260. DOI: 10.1016/j.yexcr.2018.04.015. View